Key result
Apixaban during paracentesis is linked to severe bleeding in compensated cirrhosis with moderate renal impairment.
Why the study?
The safety of paracentesis in patients with cirrhosis receiving apixaban is uncertain due to potential increased bleeding risk from impaired liver function.
Case Report (n=2)
Apixaban use during paracentesis in patients with compensated cirrhosis and moderate renal impairment may be associated with an unexpectedly high risk of severe bleeding, challenging the traditional view of it being a low-risk procedure.
Answers are grounded in this paper and cite their sources.
May warrant caution with apixaban during paracentesis in cirrhosis with renal impairment; hypothesis-generating and requires prospective validation.
We report 2 patients with compensated cirrhosis and moderate renal impairment who experienced severe bleeding complications from paracentesis during concurrent therapy with apixaban. While paracentesis has traditionally been considered a low bleeding-risk procedure and safe to perform without interruption of therapeutic anticoagulation, the increased concentrations observed in patients with impaired liver function may place these patients at unexpectedly high bleeding risk. Further investigation into the safety of paracentesis in patients with cirrhosis on apixaban may be warranted, as well as additional understanding of the clinical safety of this drug in Child-Pugh B cirrhosis.
No takes yet. Share an insight, caveat, or question.
Kuperman et al. (2022) conducted a case report in Compensated cirrhosis and moderate renal impairment (n=2). Apixaban during paracentesis was evaluated on Severe bleeding complications. Concurrent therapy with apixaban during paracentesis was associated with severe bleeding complications in two patients with compensated cirrhosis and moderate renal impairment.
Synapse has enriched 10 related papers. Consider them for comparative context: